CYTK Cytokinetics, Incorporated
Cytokinetics, Incorporated (CYTK) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $3.2M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Landry Robert E | Director | Sell | 1,000 | $74.66 | $74.7K | 9,184 −9.8% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $75.46 | $264.1K | 153,902 −2.2% of holding | |
| PARSHALL B LYNNE | Director | Sell | 5,000 | $71.48 | $357.4K | 10,784 −31.7% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 10,000 | $70.24 | $702.4K | 58,555 −14.6% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $70.24 | $526.8K | 377,820 −1.9% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $75.82 | $265.4K | 153,902 −2.2% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $76.76 | $575.7K | 377,820 −1.9% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 14,000 | $79.88 | $1.1M | 58,555 −19.3% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $80.87 | $606.5K | 377,820 −1.9% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $80.59 | $282.1K | 153,902 −2.2% of holding | |
| Blum Robert I 2 fills | President & CEO | Sell | 7,500 | $82.02 | $615.2K | 377,820 −1.9% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $86.62 | $303.2K | 153,902 −2.2% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $85.80 | $1.3M | 58,555 −20.4% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $84.92 | $636.9K | 377,830 −1.9% of holding | |
| Lee Sung | EVP, Chief Financial Officer | Sell | 1,112 | $87.79 | $97.6K | 63,221 −1.7% of holding | |
| Lee Sung | EVP, Chief Financial Officer | Sell | 3,134 | $85.00 | $266.4K | 63,221 −4.7% of holding | |
| Lee Sung | EVP, Chief Financial Officer | Sell | 38,730 | $82.30 | $3.2M | 63,221 −38% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $79.51 | $278.3K | 153,902 −2.2% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $70.46 | $528.5K | 385,330 −1.9% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.